Prevalence of PI*Z and PI*S alleles of alpha-1-antitrypsin deficiency in Finland

Jan Häggblom1*, Kaisa Kettunen2, Jussi Karjalainen3, Markku Heliövaara4, Pekka Jousilahti4 and Seppo Saarelainen5

1Sastamala Region’s Social and Health Services, Sastamala, Finland; 2Institute for Molecular Medicine Finland FIMM, Technology Center, University of Helsinki, Helsinki, Finland; 3Allergy Centre, Tampere University Hospital, Tampere, Finland; 4Department of Health, National Institute of Health and Welfare, Helsinki, Finland; 5Department of Respiratory Medicine, Tampere University Hospital, Tampere, Finland

The prevalence of PI*Z and PI*S alleles of SERPINA1 gene related to alpha-1-antitrypsin deficiency has previously been estimated to be lower in Finland than in the other countries of Northern Europe. The prevalence of PI*M (Malton) has not been studied in Finland before. We determined alpha-1-antitrypsin PI*Z and PI*S and PI*M (Malton) genotypes from a representative population sample. The number of subjects was 6,354 in the PI*S and PI*M (Malton) genotyping. PI*Z genotyping was performed in a subsample of 2,482 subjects. The allele frequencies were PI*Z 19.7/1,000 and PI*S 10.2/1,000. No PI*M (Malton) was found. The number of carriers of PI*Z and PI*S is significantly higher than previously estimated. The prevalences are in line with the findings in the neighboring countries.

Keywords: alpha-1-antitrypsin deficiency; Europe; Finland; genetic epidemiology; PI*Z; PI*S; PI*M (Malton); prevalence; SERPINA1

Received: 11 June 2015; Accepted: 2 September 2015; Published: 24 September 2015

Alpha-1-antitrypsin deficiency is an autosomal codominant inherited disorder (1). It is one of the most common hereditary disorders in Europe. Persons with MM phenotype have normal structure of the alpha-1-antitrypsin protein. Most pathology related to this disease is linked to the Z allele, and in clinical practice most of the patients have a ZZ phenotype. The remaining patients mostly have SZ, MZ, and, in a smaller amount, other rare deficiency or null phenotypes (2). Alpha1-antitrypsin deficiency results from point mutations in the SERPINA1 gene that distorts the structure of the alpha-1-antitrypsin protein. This causes an accumulation of polymers of Z alpha1-antitrypsin within hepatocytes to form inclusion bodies that are associated with juvenile cirrhosis and hepatocellular carcinoma (3). The lack of circulating protein predisposes the Z alpha1-antitrypsin homozygote to emphysema (3). M (Malton), like the Z allele, is associated with hepatic and pulmonary disease. In some Mediterranean regions, M (Malton) allele is more prevalent than Z and S alleles per 1,000 genes of all PI types (9, 10). The populations in these studies, however, have been relatively small and affected by selection. Moreover, the prevalences of PI*Z and PI*S in the neighboring countries Sweden and Estonia have been shown to be 2–3 times higher than earlier reported in Finland.

Significant differences in Y haplotype variation have been reported between eastern and western regions of Finland, indicating that two separate founder populations provided a substantial contribution to the Finnish gene pool (11). This has raised a question whether there is also a significant east–west difference in alpha1-antitrypsin deficiency in Finland, since the prevalence of the Z allele has been estimated to be very low in the northeastern parts of Finland (8). The aim of our present paper was to determine the prevalences of PI*Z, PI*S, and PI*M...
Genotyping
Genotyping of the alpha-1-antitrypsin gene (SERPINA1) was performed at FIMM Technology Centre, University of Helsinki. Genotyping of the M (Malton) allele and S allele (rs17580) was performed using the Agena MassARRAY system and the iPLEX Gold assays (Agena Bioscience, San Diego, CA, USA). In this method, allele discrimination is based on primer extension with single mass-modified nucleotides followed by MALDI-TOF mass spectrometry. All reactions are designed in multiplexes of up to 35 SNPs, by use of Assay Design v2.0 software (Agena Bioscience). Genotyping reactions were performed on 20 ng of dried genomic DNA in 384-well plate formats according to manufacturer’s recommendations. Concentrations of the extension primers were adjusted according to their mass and varied between 7 and 24.6 μM. The data were collected using the MassARRAY Compact System (Agena Bioscience), and the genotypes were called using Typer 4 software (Agena Bioscience). The Z allele (rs28929474) variation was assessed by use of TaqMan SNP Endpoint genotyping (Applied Biosystems, Foster City, CA, USA) on the LightCycler 480 system (Hoffmann-La Roche Ltd, Basel, Switzerland). A total of 2,496 DNA samples and 25 duplicate samples were run. Eighteen of the samples genotyped had no signal at all or were discarded manually as not reliable due to very low signal intensity. For quality control reasons, the genotype calls on both genotyping systems were checked manually and corrected when necessary. In addition, genotyping quality of all assays was examined by a detailed QC procedure consisting of success rate check, duplicated samples, water controls, and Hardy–Weinberg Equilibrium testing.

Discussion
Severe early onset of emphysema caused by the deficiency of alpha-1-antitrypsin was first described in 1963 (13). Soon after this discovery, Fagerholm et al. (8) published the prevalences of serum PI types in some Lappish and Finnish populations. The phenotypes of 468 Lappish persons were determined, and only one Finnish Lapp had the phenotype MZ. Though, the Z allele was practically not found at all in the Lappish population. Moreover, 222 Finns (other than Lappish) were studied, and the frequency of PI*Z was 4.5/1,000 and the PI*S allele was not found at all. In the study by Arnaud et al. (6), alpha-1-antitrypsin phenotypes of 548 normal Finnish persons were determined by isoelectric focusing in polyacrylamide gel. The frequencies obtained were PI*Z 13.7/1,000 and PI*S 17.3/1,000. Furthermore, Arvilommi (7) determined these alleles from a population of 1,037. The population material comprised 1,037 serum samples from healthy blood donors (with no medications) in Turku, a town in western Finland in 1970. The allele frequencies were PI*Z 6.7/1,000 and PI*S 4.8/1,000.

We determined alpha-1-antitrypsin PI*Z and PI*S genotypes from a representative Finnish population sample. The genotyping of the PI*Z allele on Agena MassARRAY
turned out to be methodologically difficult. There are other SNPs in the close vicinity of PI*Z that interfere with the SNP of interest and make assay design impossible.

The PI*Z allele genotyping was instead performed using TaqMan SNP Endonuclease genotyping on the LightCycler 480 system. Because of this fact and due to a limited research

**Table 1.** Allele frequencies and number of carriers in Finnish population. The total population in Finland (year 2000) used in these calculations was 5,181,000 (taken from Statistics Finland year 2000)

| Allele frequencies | Allele frequencies (total number of alleles per 1,000 genes of all PI types) | Number of carriers in Finnish population |
|-------------------|-----------------------------------------------------------------------------|-----------------------------------------|
| Sample size       | (%)                                                                         |                                         |
| PI*Z              | 2,482                                                                      | 3.91                                    | 202,577                                  |
| PI*S              | 6,354                                                                      | 2.04                                    | 105,692                                  |
| PI*M (Malton)     | 6,354                                                                      | 0.00                                    | 0                                        |
grant, we had to cut down our sample size regarding the Z allele to 2,496 persons. The subsample was geographically balanced to allow analyses regarding an east–west difference. Despite sample size reduction, the studied population was still significantly bigger than in the earlier papers.

According to our study, the prevalence of PI*S allele in Finland is slightly lower than in Scandinavia where the prevalence is around 20/1,000 (10). The PI*Z prevalence in Scandinavia has been reported to be around 20–30/1,000, as seems to be the case in Finland too. We also analyzed whether there is an east–west difference in these prevalences as the earlier studies suggested. Although PI*Z was slightly more common in the western part of the country, no statistically significant differences between these two regions were found.

In conclusion, we determined the prevalences of alpha-1-deficiency alleles PI*Z, PI*S, and PI*M (Malton) in the Finnish population. The number of carriers of the two most common deficiency alleles (PI*Z and PI*S) is significantly higher than previously estimated. The prevalences are in line with the findings in the neighboring countries, and no clear difference was found between eastern and western parts of the country.

Acknowledgements

This work was supported by Tampere Tuberculosis Foundation. The authors thank Mrs. Paivi Lahermo for excellent determination of the M (Malton) and S alleles. The authors also thank Paul Knekt for skillful statistical assistance.

Conflict of interest and funding

The authors have no conflicts of interest.

References

1. Luisetti M, Seersholm N. A1-antitrypsin deficiency-1: epidemiology of a1-antitrypsin deficiency. Thorax. 2004; 59: 164–9.
2. ATS/ERS Task Force. American Thoracic Society/European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003; 168: 818–900.
3. Lomas DA. Loop-sheet polymerization: the mechanism of the alpha-1-antitrypsin deficiency. Respir Med. 2000; 94: S3–6.
4. Orru G, Gavino F, Pilial S, Pilloni L, Montaldo C, Puca G, et al. Rapid PCR real-time genotyping of M-Malton alpha1-antitrypsin deficiency alleles by molecular beacons. Diagn Mol Pathol. 2005; 14: 237–42.
5. Curiel DT, Holmes MD, Okayama H, Vogelmeier C, Travis WD, et al. Molecular basis of the liver and lung disease associated with the alpha-1-antitrypsin deficiency allele M-Malton. J Biol Chem. 1989; 264: 13938–45.
6. Arnaud P, Koistinen J, Wilson GB, Fudenberg HH. Alpha-1-antitrypsin (Pi) phenotypes in a Finnish population. Scand J Clin Lab Invest. 1977; 37: 339–43.
7. Arvilommi H. Studies on serum Pi- and C3-polymorphism in Finland. Acta Pathol Microbiol Scand. 1972; 1972: 234: 1–50.
8. Fagerholm MK, Eriksson AW, Monn E. Serum Pi types in some Lappish and Finnish populations. Hum Hered. 1969; 19: 360–4.
9. Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha-1-antitrypsin deficiency in European countries. Eur Respir J. 2006; 27: 77–84.
10. de Serres FJ, Blanco I. Prevalence of a1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012; 6: 277–95.
11. Kittles RA, Perola M, Peltonen L, Bergen AW, Aragon RA, Virkkunen M, et al. Dual origins of Finns revealed by Y chromosome haplotype variation. Am J Hum Genet. 1998; 62: 1171–9.
12. Koskinen S, Laiho J, Rinne S, Kuosmanen N, Alha P, Rissanen H, et al. Participation, complementary data collection, and other measures to increase participation rate. In: Heistaro S, editor. Methodology report health 2000 survey. KTL B 26/2008. Available from: http://www.terveys2000.fi/doc/methodologyrep.pdf [cited 17 September 2015].
13. Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963; 15: 132–40.